Sarnak              M.J., Levey A.S., Schoolwerth A.C. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention // Circulation. - 2003. - Vol. 108. - P. 2154-2169.
Brosius F.C., 3rd, Hostetter T.H., Kelepouris E. et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council. - the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention. - and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation // Circulation. - 2006. - Vol. 114. - P. 1083-1087.
3.Stevens L.A., Coresh J., Greene T. et al. Assessing kidney function-measured and estimated glomerular filtration rate // N. Engl. J. Med. - 2006. - Vol. 354. - P. 2473-2483.
Van              Biesen W., De Bacquer D., Verbeke F. et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years // Eur. Heart J. - 2007. - Vol. 28. - P. 478-483.
Tonelli              M., Jose P., Curhan G. et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial // BMJ. - 2006. -
Vol. 332. - P. 1426.
Anavekar              N.S., McMurray J.J., Velazquez E.J. et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction // N. Engl. J. Med. - 2004. - Vol. 351. - P. 1285-1295.
Messerli              F.H., Mancia G., Conti C.R. et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? // Ann. Intern. Med. - 2006. -
Vol. 144. - P. 884-893.
Mancia              G., De Backer G., Dominiczak A. et al. 2007. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25. - P. 1105-1187.
de              Zeeuw D., Remuzzi G., Parving H.H. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2. diabetic patients with nephropathy // Circulation. - 2004. - Vol. 110. - P. 921-927.
Keith              D.S., Nichols G.A., Gullion C.M. et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization // Arch. Intern. Med. - 2004. - Vol. 164.
P. 659-663.
Tonelli              M., Sacks F., Pfeffer M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease // Circulation. - 2005. - Vol. 112. - P. 2627-2633.
Fliser              D., Kronenberg F., Kielstein J.T. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study // J. Am. Soc. Nephrol. - 2005. - Vol. 16. -
P. 2456-2461.
Wanner              C., Krane V., Marz W. et al. Atorvastatin in patients with type 2. diabetes mellitus undergoing hemodialysis // N. Engl. J. Med. - 2005. - Vol. 353. - P. 238-2348.
Parfrey              P.S., Foley R.N., Harnett J.D. et al. Outcome and risk factors for left ventricular disorders in chronic uraemia // Nephrol. Dial. Transplant. - 1996. - Vol. 11. - P. 1277-1285.
Herzog              C.A., Ma J.Z., Collins A.J. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes // Circulation. - 2002. - Vol. 106. - P. 2207-2211.
Herzog              C.A., Strief J.W., Collins A.J. et al. Cause-specific mortality of dialysis patients after coronary revascularization: why don’t dialysis patients have better survival after coronary intervention? // Nephrol. Dial. Transplant. - 2008. - Vol. 23. - P. 2629-2633.
Dangas              G., Iakovou I., Nikolsky E. et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables // Am. J. Cardiol. -
- Vol. 95. - P. 13-19.
Waikar              S.S., Bonventre J.V. Biomarkers for the diagnosis of acute kidney injury // Nephron. Clin.
Pract. - 2008. - Vol. 109: c192-c197.
19.Solomon R., Werner C., Mann D. et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents // N. Engl. J. Med. - 1994. - Vol. 331. - P. 1416-1420.
Mueller C., Buerkle G., Buettner H.J. et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2. hydration regimens in 1620. patients undergoing coronary angioplasty // Arch. Intern. Med. - 2002. - Vol. 162. - P. 329-336.
21 .Tepel M., van der Giet M., Schwarzfeld C. et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine // N. Engl. J. Med. - 2000. - Vol. 343. - P. 180-184.
Merten              G.J., Burgess W.P., Gray L.V. et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial // JAMA. - 2004. - Vol. 291. - P. 2328-2334.
Aspelin              P., Aubry P., Fransson S.G. et al. Nephrotoxic effects in high-risk patients undergoing angiography // N. Engl. J. Med. - 2003. - Vol. 348. - P. 491-499.
24.Shellock F.G., Spinazzi A. MRI safety update. - 2008. - Vol. P. part 1, MRI contrast agents and nephrogenic systemic fibrosis // AJR Am. J. Roentgenol. - 2008. - Vol. 191. - P. 1129-1139.
25.Steen H., Giannitsis E., Sommerer C., Bahner U., Brandl M., Merbach C., Merten C., Ritz E., Katus
A., Zeier M., Schwenger V. Acute phase reaction to gadolinium-DTPA in dialysis patients // Nephrol Dial Transplant. - 2009. - Vol. 24. - P. 1274-1277.
KDOQI.              - National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease // Am. J. Kidney Dis. - 2006. -
Vol. 47(5. Suppl.3): S11-145.
Bakris              G.L., Hart P., Ritz E. Beta blockers in the management of chronic kidney disease // Kidney Int. -
- Vol. 70. - P. 1905-1913.
Cice              G., Ferrara L., D’Andrea A. et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 1438-1444.
29.Solomon S.D., Rice M.M., A Jablonski K. et al. Renal function and effectiveness of angiotensin- converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial // Circulation. - 2006. - Vol. 114. - P. 26-31.
Zannad F., Kessler M., Lehert P. et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies // Kidney Int. - 2006. - Vol. 70.
P. 1318-1324.
31 .Hou F.F., Zhang X., Zhang G.H. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency // N. Engl. J. Med. - 2006. -
Vol. 354. - P. 131-140.
32.Verbalis J.G., Goldsmith S.R., Greenberg A. et al. Hyponatremia Treatment Guidelines. - 2007. - Vol. P. expert Panel Recommendations // Am. J. Med. - 2007. - Vol. 120: S1-S21.